Background
==========

Angioid streaks (AS) are visible irregular crack-like dehiscences radiating from the optic nerve to the peripheral retina. Approximately 70% of AS patients have pseudoxanthoma elasticum (PXE) characterized by changes in the elastic tissue of the skin \[[@B1]\]. Patients with AS are usually asymptomatic unless the lesions extend towards the fovea or develop complications such as traumatic Bruch's membrane rupture or choroidal neovascularization (CNV). Several studies on the relationship between ocular trauma and subretinal hemorrhage in patients with AS have been reported \[[@B2],[@B3]\]. There is also a report of an AS patient who developed CNV after indirect trauma to the eye itself \[[@B4]\]. It has also been reported that 15% of AS patients who suffer head injuries develop significant visual impairment \[[@B5]\]. However, to our knowledge, there have been no reports of any AS patients in whom CNV occurred after vitrectomy surgery.

We report herein a case of an AS patient in whom CNV occurred at 7 weeks after microincision vitrectomy surgery for removal of epiretinal membrane (ERM).

Case presentation
=================

A 76-year-old male patient with a medical history of hypertension but no eye surgery reported distorted vision in the left eye. Best corrected visual acuity (BCVA) at his initial examination was 1.2 (with +1.75 diopter (dpt), cylinder (cyl) -1.25 dpt Ax 110°) in his right eye and 0.6 (with +2.75 dpt, cyl. -1.50 dpt Ax 90°) in his left eye. Using the IOLMaster 500 (Carl Zeiss Meditec AG, Dublin, CA, USA), his axial lengths were determined to be 23.3 and 23.1 mm in his right and left eyes, respectively. Except for mild senile cataracts in the anterior segments and media of both of his eyes, there were no abnormalities found. Intraocular pressures were 13 mmHg on the right and 11 mmHg on the left. Fundus examination showed ERM in the left eye, in addition to bilateral AS. Although spectral-domain optical coherence tomography (OCT; Cirrus HD-OCT, Carl Zeiss Meditec AG) using the high-definition 5-line raster scan protocol (horizontal scan of 6 mm) revealed ERM, CNV was not observed in the macula of his left eye (Figure [1](#F1){ref-type="fig"}a). The patient subsequently underwent 23-gauge three-port pars plana vitrectomy with removal of ERM combined with cataract surgery at The Jikei University, Daisan Hospital. Indocyanine green dye was used to visualize the internal limiting membrane (ILM). The ILM in addition to the ERM were successfully peeled and removed (Figure [1](#F1){ref-type="fig"}b). No retinal hemorrhage was noted during the vitreous surgery (Figure [1](#F1){ref-type="fig"}b), and his left BCVA subsequently improved to 0.8.

![**Optical coherence tomography before surgery and fundus photograph of patient during vitrectomy surgery.a**) Epiretinal membrane (ERM) in optic coherence tomography before vitrectomy surgery. **b**) Fundus photograph during vitrectomy surgery. The ERM is successfully peeled before ILM peeling.](1471-2415-13-29-1){#F1}

Seven weeks after the vitrectomy surgery, an elevated lesion with retinal hemorrhage due to probable CNV was found between the fovea and the optic disc in his left eye (Figure [2](#F2){ref-type="fig"}), although he had no history of any ocular trauma after the surgery. One week later, his left BCVA decreased to 0.15 and the retinal hemorrhage expanded. Although posterior sub-Tenon injection of triamcinolone acetonide was performed, no visual improvement was seen.

![**Left fundus finding 7 weeks after the vitrectomy surgery.** Photograph shows an elevated lesion with retinal hemorrhage that is most likely due to probable choroidal neovascularization found between the fovea and the optic disc.](1471-2415-13-29-2){#F2}

At 12 weeks after the vitrectomy surgery at The Jikei University Hospital, his BCVA was 0.08 in his left eye. Fundus examination revealed a radiating dark brownish line from the optic disc head in his right (Figure [3](#F3){ref-type="fig"}a) and left (Figure [3](#F3){ref-type="fig"}b) eyes, and there was an elevated subretinal lesion with retinal hemorrhage in his left macula (Figure [3](#F3){ref-type="fig"}b). Although OCT showed no abnormal findings in his right eye (Figure [3](#F3){ref-type="fig"}c), Gass type 2 CNV with macular edema was observed in his left eye (Figure [3](#F3){ref-type="fig"}d). Fluorescein angiography (FA) revealed well-defined (classic) CNV from the early (Figure [3](#F3){ref-type="fig"}e) to late phases (Figure [3](#F3){ref-type="fig"}f) in the left macula. Using indocyanine green angiography (ICGA), we were able to visualize the CNV from the early (Figure [3](#F3){ref-type="fig"}g) to late phases (Figure [3](#F3){ref-type="fig"}h).

![**Fundus findings prior to the initial anti-vascular endothelial growth factor therapy.a**, **b**) Fundus photographs show angioid streaks in the right (**a**) and left (**b**) eyes and choroidal neovascularization (CNV) in the left macula (**b**). **c**, **d**) Optical coherence tomography shows no abnormal finding in the right eye (**c**) and Gass type 2 CNV with macular edema in the left eye (**d**). **e**, **f**) Fluorescein angiograms show well-defined (classic) CNV in the early (**e**) to late phases (**f**) in the left macula. **g**, **h**) Indocyanine green angiograms show CNV is visualized from the early (**g**) to late phases (**h**) in the left macula.](1471-2415-13-29-3){#F3}

Over the next 6 months, a total of 5-time intravitreal injections of the anti-vascular endothelial growth factor (VEGF) drug, bevacizumab (Avastin, Genentech, San Francisco, CA, USA), were given. His left BCVA remained at 0.1. Fundus examination demonstrated that there was no regression of the CNV (Figure [4](#F4){ref-type="fig"}a), as was confirmed by OCT (Figure [4](#F4){ref-type="fig"}b). The FA images indicated there was a foveal lesion with evidence of classic CNV in the early phase (Figure [4](#F4){ref-type="fig"}c) and an extended high fluorescent lesion in the late phase (Figure [4](#F4){ref-type="fig"}d).

![**Left fundus findings after 5 intravitreal bevacizumab injections.a**) Fundus photograph indicates there is no regression of the choroidal neovascularization (CNV). **b**) Optical coherence tomography also confirms there is no regression of the CNV. **c**, **d**) Fluorescein angiograms show evidence of classic CNV in the early (**c**) to the late phases (**d**).](1471-2415-13-29-4){#F4}

Subsequently, we performed standard-fluence photodynamic therapy (PDT: laser fluence set at 50 J/cm^2^) with full-dose verteporfin (Visudyne; Novartis Pharma AG, Basel, Switzerland) in combination with an intravitreal ranibizumab (Lucentis, Genentech) (IVR) injection. After this combination treatment, 3 additional IVR treatments were performed. At 4 months after the combination treatment, his BCVA improved to 0.5. There was a marked regression of the CNV size observed in both the fundus (Figure [5](#F5){ref-type="fig"}a). OCT showed significant but incomplete regression of CNV, and persistence of intra-retinal cysts (Figure [5](#F5){ref-type="fig"}b). The FA images revealed that leakage from the CNV noted in the early phases (Figure [5](#F5){ref-type="fig"}c) almost completely disappeared by the late phases (Figure [5](#F5){ref-type="fig"}d).

![**Left fundus findings 4 months after the combination treatment.a**) Fundus photograph shows marked regression of the choroidal neovascularization (CNV). **b**) Optical coherence tomography shows significant but incomplete regression of CNV, and persistence of intra-retinal cysts. **c**, **d**) Fluorescein angiograms show that leakage from the CNV almost completely disappears between the early (**c**) and late phases (**d**).](1471-2415-13-29-5){#F5}

Examination of the skin on the neck showed suggestive of PXE. A skin biopsy was performed from the lesion on the neck. The histological section of the biopsy revealed short and broken elastic fibers with dark staining of calcium deposits by Von Kossa staining in the reticular dermis (Figure [6](#F6){ref-type="fig"}), convincing a diagnosis of PXE.

![**Histological findings of a skin biopsy on the neck.** The histological section reveals short and broken elastic fibers with dark staining of calcium deposits by Von Kossa staining in the reticular dermis, convincing a diagnosis of pseudoxanthoma elasticum.](1471-2415-13-29-6){#F6}

Discussion
==========

In this report, we describe a single AS patient in whom CNV developed 7 weeks after vitrectomy surgery for ERM. To date, there have been no other reports of any AS patients who have developed CNV after vitrectomy surgery.

Numerous studies have reported the incidence of CNV to vary between 72%--86% in AS patients \[[@B5]\]. It is reported that the risk of developing CNV increases with age \[[@B6]\]. Other risk factors comprise the width, length and location of the AS. Several studies have reported that wider and longer AS are associated with higher risk of CNV, and that the risk of CNV development is especially higher if AS are located within one optic disc diameter from the foveola \[[@B5],[@B7],[@B8]\].

As an external factor, ocular trauma can be a risk factor for the development of subretinal hemorrhage \[[@B2],[@B3]\]. In fact, AS patients are likely to develop breaks of Bruch's membrane even after relatively mild ocular head injuries, since their Bruch's membrane is brittle \[[@B5]\]. In addition, it has also been reported that an AS patient developed CNV 4 months after an indirect ocular trauma \[[@B4]\]. Thus, it is possible that CNV can occur due to either direct or indirect ocular trauma.

Regarding the relationship between vitrectomy surgery and CNV development, there have been some studies that have reported finding CNV after vitrectomy surgery for idiopathic macular hole \[[@B9]-[@B12]\]. Although the pathogenesis underlying the development of CNV after macular hole surgery has yet to be completely clarified, it has been suggested that the most plausible explanation is an age-related degenerative change in the retinal pigment epithelium (RPE) and Bruch's membrane. This is supported by the fact that there is a higher prevalence of CNV development after macular hole surgery in older patients \[[@B10],[@B13]\]. In addition, as has been reported in a previous study, mechanical trauma during the ILM peeling in the macular hole surgery might have played a role in the pathogenesis of the CNV that subsequently developed in the patient \[[@B10]\]. In fact, this is similar to the current case, as our patient had brittleness of Bruch's membrane and RPE because of AS and aging and thus, underwent vitrectomy surgery with ERM and ILM peeling, after which he developed CNV.

When treating CNV secondary to AS, previous studies have described the use of monotherapy treatments employing PDT or anti-VEGF therapies. For example, Arias et al. reported that PDT was not effective in the treatment of CNV in the macula \[[@B14]\], while Browning et al. showed that PDT delayed, but did not permanently prevent visual loss associated with the CNV in AS \[[@B15]\]. However, in other cases it has been reported that injection of intravitreal bevacizumab (IVB) was effective as a long-term control tool for CNV associated with AS \[[@B16],[@B17]\]. Moreover, it has been reported that IVR was also effective in treating CNV associated with AS \[[@B18]-[@B20]\]. Even so, after the patient in the current case received 5-time IVB injections, the CNV remained active. This suggested that there was a decrease in the biologic effect after repeated intravitreal anti-VEGF injections of the same drug, such as bevacizumab \[[@B21]-[@B23]\]. An *in vitro* experiment demonstrated that the absence or presence of hyaluronan, which is a major component in the vitreous body, may be associated with the clinical efficacy of IVB because of the higher affinity of hyaluronan for bevacizumab as compared to that for ranibizumab \[[@B24]\]. Christoforidis et al. revealed that clearance rates for intravitreally placed bevacizumab or ranibizumab in vitrectomized or lensectomized rabbit model eyes are faster than those in control eyes \[[@B25]\]. Based on these previous findings in conjunction with the bevacizumab tachyphylaxis and the vitrectomized-pseudophakic condition that was present, we decided to use ranibizumab instead of bevacizumab in all of the subsequent treatments for this patient. Recently, it has been reported that the combination of IVR and reduced-fluence PDT for CNV associated with AS was effective in the regression of CNV and in improving (or stabilizing) the visual acuity \[[@B26],[@B27]\]. Based on the above-mentioned findings, we performed the combined therapy of full-dose PDT and IVR instead of IVR monotherapy. Our current results support the effectiveness of the combined therapy, as the combination therapy of full-dose PDT and IVR was effective, with improvement of the visual acuity and regression of the CNV ultimately seen in our patient.

Conclusions
===========

Development of CNV can occur in elderly patients with AS after vitrectomy surgery. In such cases, the combination of PDT and anti-VEGF therapies may be considered for use as the initial treatment of CNV.
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